RNA Formulation Videos

  1. What Does 2025 (And Beyond) Hold For The RNA-LNP Space? 12/4/2024

    Three LNP experts share their thoughts on the incremental advancements they’d like to see the RNA-LNP space make in the next few years.

  2. Novel Lipid Chemistries And Their Impact On Passive LNP Delivery 2/24/2026

    In this Advancing RNA Live clip, NanoVation’s Dominik Witzigmann and Stealth Co’s John Zuris break down the scientific advancements we’re seeing for each of an LNP’s components (i.e., the ionizable lipid, helper lipid, and PEG), albeit with the caveat that, with these advancements, Freedom to Operate (FTO) continues to grow increasingly complicated.

  3. Unlocking The Next Wave Of Cancer Vaccines 4/21/2026

    Discover how advanced ionizable LNP formulations and scalable manufacturing strategies can accelerate the development and clinical translation of personalized cancer vaccines.

  4. R&D & CMC Priorities For LNPs Beyond Cell-Specific Delivery 12/4/2024

    It goes without saying that achieving cell-specific delivery is the most often discussed challenge facing the RNA-LNP field near- and long-term. However, as these three LNP experts share in this Advancing RNA Live clip, they have a whole list of additional R&D and CMC priorities we must address/accomplish to improve RNA-LNPs’ efficacy in personalized and gene therapy approaches.

  5. Enhancing Gene Editing Outcomes And Safety for Clinical Translation 5/6/2026

    Learn how streamlined vector backbones can improve efficiency, consistency, and expression durability when reliability matters most.

  6. Practical Applications For Controlled And Safe Nucleic Acid Delivery 7/21/2025

    Explore the science behind LNP formulation development, from ionizable lipids to scalable manufacturing through case studies, screening strategies, and flexible approaches for advancing next-generation therapeutics.

  7. Goldilocks & The 3…CQAs? Finding "Just Right" With LNP Optimization 12/4/2024

    Three LNP experts from Sanofi, Hopewell Therapeutics, and BioNTech collectively discuss how far we’ve come in understanding the structure of our LNPs while also shedding light on the variables that have the greatest potential of causing shifts in our products’ structure/function.

  8. Modular Liquid Nanoparticle (LNP) Systems 12/6/2024

    Optimize your lipid nanoparticle (LNP) production with KNAUER's modular systems. Maximize flexibility, scalability, and control to meet the needs of your project.

  9. What Innovations Could Help Us Overcome Preclinical Model Limitations For RNA-LNPs? 12/4/2024

    In this Advancing RNA Live clip, BioNTech’s Ben Muir and Hopewell Therapeutics’ Kate Zhang share their perspectives on the most exciting novel screening methods, innovative preclinical models, and next-gen technologies they hope can/will eventually help us bridge the translation gap between preclinical models and the clinic.